Thrombocytopenia Market Expected to Expand at a Healthy Growth Rate by (2022-2032), Says DelveInsight | Key companies – UCB Biopharma, Principia Biopharma, Baxalta/Takeda, Argenx


DelveInsight’s “Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2032” report provides an in-depth understanding of thrombocytopenia, historical and forecasted epidemiology, and trends in the thrombocytopenia market in the US, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The thrombocytopenia market is expected to rise owing to the growing prevalence and awareness of the disease over the forecast period. Additionally, the launch of various multi-stage thrombocytopenia pipeline products will significantly revolutionize the thrombocytopenia market dynamics.

by DelveInsightThrombocytopenia Market Market Insights, Epidemiology and Forecast-2032″ The report offers an in-depth understanding of thrombocytopenia, historical and forecasted epidemiology as well as thrombocytopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and the Japan.

Overview of Thrombocytopenia

Thrombocytopenia is a condition in which the blood contains a lower than normal number of fragments of blood cells called platelets. Platelets are made in the bone marrow along with other types of blood cells. They travel through the blood vessels and stick together (clot) to stop any bleeding that may occur if a blood vessel is damaged. Platelets are also called thrombocytes because a clot is also called a thrombus. When a patient’s blood has too few platelets, mild to severe bleeding can occur. Bleeding can occur inside the body (internal bleeding) or under the skin, or on the surface of the skin (external bleeding).

Symptoms of thrombocytopenia

Symptoms of thrombocytopenia include –

  • Prolonged bleeding from cuts
  • Bleeding gums or nose
  • Blood in urine or stool
  • Abnormally heavy menstrual flow
  • Body fatigue
  • Easy or excessive bruising (purpura)

Some of the key facts from the Thrombocytopenia Market report:

  • Thrombocytopenia market size was estimated at USD 4,142 million in 2021 and is expected to grow with significant CAGR during the study period (2019-2032)
  • Mild to severe bleeding causes the main signs and symptoms of thrombocytopenia. Bleeding can occur inside the body (internal bleeding) or under the skin, or on the surface of the skin (external bleeding)
  • The total number of thrombocytopenia cases in 7MM was 1,653,934 cases in 2021
  • The United States had the highest number of thrombocytopenia cases among 7MM. The total number of thrombocytopenia cases in the United States was estimated at 467,078 cases in 2021
  • Germany ranked second for thrombocytopenia cases among 7MM. In 2021, Germany had 325,202 cases of thrombocytopenia
  • Main thrombocytopenia companies: UCB Biopharma, Principia Biopharma, Baxalta/Takeda, Argenx and others
  • Key treatments for thrombocytopenia: Rozanolixizumab (UCB7665), Rilzabrutinib (PRN-1008), TAK-755 (BAX930/SHP655), Efgartigimod (ARGX-113) and others

Get a free sample for the Thrombocytopenia Market Report

Key Highlights of the Thrombocytopenia Market Report:

  1. The Thrombocytopenia Market report covers a descriptive overview and comprehensive overview of the Epidemiology of Thrombocytopenia and Thrombocytopenia in 7MM market (US, EU5 (Germany, Spain, France, Italy, UK ) and Japan.)
  2. The Thrombocytopenia Market report provides information on current and emerging therapies.
  3. The Thrombocytopenia Market report provides historical and forecasted global market covering the spread of drugs in 7MM.
  4. The Thrombocytopenia Market report provides an advantage which will help in developing business strategies by understanding the trends shaping and driving the Thrombocytopenia market.

Learn More About Therapies Targeted to Capture Major Thrombocytopenia Market Share @ Thrombocytopenia Market Forecast

Segmentation of thrombocytopenia epidemiology:

The Thrombocytopenia Market report offers epidemiological analysis for the study period 2019-2032 in 7MM segmented into:

  • Total prevalence of thrombocytopenia
  • Prevalent cases of thrombocytopenia by severity
  • Sex-specific prevalence of thrombocytopenia
  • Diagnosed cases of episodic and chronic thrombocytopenia

Thrombocytopenia Market

The thrombocytopenia market dynamics are expected to change in the coming years owing to the expected launch of emerging therapies such as rilzabrutinib, TAK-755 and others during the forecast period 2019-2032.

Download the report to understand which factors drive epidemiological trends in thrombocytopenia @ Thrombocytopenia Epidemiological Overviews

Thrombocytopenia Market Drivers

  • Arrival of effective therapies on the market
  • Higher chance of drug approval for thrombocytopenia
  • Increased prevalence of thrombocytopenia
  • Increase in monetary support by the government
  • Increased patient compliance
  • Robust Thrombocytopenia Pipeline

Thrombocytopenia Therapies

  • Rozanolixizumab(UCB7665)
  • Rilzabrutinib (PRN-1008)
  • TAK-755 (BAX930/SHP655)
  • Effartigimod(ARGX-113)

Key Thrombocytopenia Companies

  • UCB Biopharma
  • Principia Biopharma
  • Baxalta/Takeda
  • Argenx

Scope of the Thrombocytopenia Market Report

  • Study period: 2019-2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Main thrombocytopenia companies: UCB Biopharma, Principia Biopharma, Baxalta/Takeda, Argenx and others
  • Key treatments for thrombocytopenia: Rozanolixizumab (UCB7665), Rilzabrutinib (PRN-1008), TAK-755 (BAX930/SHP655), Efgartigimod (ARGX-113) and others
  • Therapeutic Assessment: Currently Marketed Thrombocytopenia and Emerging Thrombocytopenia Therapies
  • Thrombocytopenia Market Dynamics: Thrombocytopenia Market Drivers and Barriers
  • Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG matrix, market entry strategies
  • Unmet Needs, KOL Views, Analyst Views, Thrombocytopenia Market Access and Reimbursement

Thrombocytopenia Market Barriers

  • Economic burden
  • Poor knowledge of the disease and delay in the diagnosis of thrombocytopenia
  • Complications Associated with Current Thrombocytopenia Therapies

Contents

1. Overview of the Thrombocytopenia Market Report

2. Executive Summary for Thrombocytopenia

3. SWOT analysis of thrombocytopenia

4. Share of patients with thrombocytopenia (%) Overview at a glance

5. Thrombocytopenia Market Overview at a Glance

6. Background and Overview of Thrombocytopenia Disease

7. Epidemiology of thrombocytopenia and patient population

8. Country-specific patient population with thrombocytopenia

9. Thrombocytopenia Current Treatment and Medical Practices

10. Thrombocytopenia Unmet needs

11. Thrombocytopenia Emerging Therapies

12. Thrombocytopenia Market Outlook

13. Thrombocytopenia Market Analysis by Countries (2019-2032)

14. Access to the thrombocytopenia market and reimbursement of therapies

15. Thrombocytopenia Market Drivers

16. Thrombocytopenia Market Barriers

17. Thrombocytopenia Appendix

18. Thrombocytopenia Reporting Methodology

19. DelveInsight Abilities

20. Disclaimer

21. About DelveInsight

To learn more about treating thrombocytopenia, visit @ Drugs for thrombocytopenia

Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Gaurav Bora
E-mail: Send an email
Call: 9193216187
Address:304 S. Jones Boulevard #2432
Town: Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Previous Map of Residents Plan Update Recommendations for City Officials
Next JD (U) Flays Bihar BJP Chief on population growth rate figures